## Silvia Svegliati Baroni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/891603/publications.pdf

Version: 2024-02-01

304743 361022 36 2,228 22 35 citations h-index g-index papers 39 39 39 2619 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis. New England Journal of Medicine, 2006, 354, 2667-2676.	27.0	549
2	Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood, 2007, 110, 237-241.	1.4	212
3	Oxidative stress in scleroderma: Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis and Rheumatism, 2001, 44, 2653-2664.	6.7	211
4	Platelet-derived Growth Factor and Reactive Oxygen Species (ROS) Regulate Ras Protein Levels in Primary Human Fibroblasts via ERK1/2. Journal of Biological Chemistry, 2005, 280, 36474-36482.	3.4	151
5	Reactive Oxygen Species Are Required for Maintenance and Differentiation of Primary Lung Fibroblasts in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2010, 5, e14003.	2.5	122
6	Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood, 2013, 122, 4111-4118.	1.4	90
7	Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Science Signaling, 2014, 7, ra84.	3.6	84
8	New Insights into the Role of Oxidative Stress in Scleroderma Fibrosis. Open Rheumatology Journal, 2012, 6, 87-95.	0.2	65
9	Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Scientific Reports, 2017, 7, 14874.	3.3	65
10	Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Seminars in Immunopathology, 2008, 30, 329-337.	6.1	58
11	A Reactive Oxygen Species–Mediated Loop Maintains Increased Expression of NADPH Oxidases 2 and 4 in Skin Fibroblasts From Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 1611-1622.	5.6	54
12	Pathogenic autoantibodies in systemic sclerosis. Current Opinion in Immunology, 2007, 19, 640-645.	5.5	44
13	Induction of Scleroderma Fibrosis in Skinâ€Humanized Mice by Administration of Antiâ^'Plateletâ€Derived Growth Factor Receptor Agonistic Autoantibodies. Arthritis and Rheumatology, 2016, 68, 2263-2273.	5.6	42
14	HaRas activates the NADPH oxidase complex in human neuroblastoma cells via extracellular signal-regulated kinase 1/2 pathway. Journal of Neurochemistry, 2004, 91, 613-622.	3.9	40
15	Solid monounsaturated diet lowers LDL unsaturation trait and oxidisability in hypercholesterolemic (Type IIb) patients. Free Radical Research, 1999, 30, 275-285.	3.3	37
16	Intracellular free radical production by peripheral blood T lymphocytes from patients with systemic sclerosis: role of NADPH oxidase and ERK1/2. Arthritis Research and Therapy, 2015, 17, 68.	3.5	34
17	Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. PLoS ONE, 2018, 13, e0196048.	2.5	34
18	Stimulatory autoantibodies to the PDGF receptor: A link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmunity Reviews, 2007, 7, 121-126.	5.8	33

#	Article	IF	CITATIONS
19	Epitope Specificity Determines Pathogenicity and Detectability of Anti–Plateletâ€Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 1891-1903.	5.6	32
20	Metabolomic profile of systemic sclerosis patients. Scientific Reports, 2018, 8, 7626.	3.3	30
21	NADPH oxidase, oxidative stress and fibrosis in systemic sclerosis. Free Radical Biology and Medicine, 2018, 125, 90-97.	2.9	29
22	Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro. Frontiers in Immunology, 2017, 8, 75.	4.8	25
23	Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease. Journal of Rheumatology, 2018, 45, 630-637.	2.0	23
24	Agonistic antibodies in systemic sclerosis. Immunology Letters, 2018, 195, 83-87.	2.5	22
25	Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis. Rheumatology, 2021, 60, 92-102.	1.9	18
26	Characterization of the c-Myb-responsive Region and Regulation of the Human Type I Collagen $\hat{l}\pm 2$ Chain Gene by c-Myb. Journal of Biological Chemistry, 2003, 278, 1533-1541.	3.4	17
27	Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 2022, 10, 163.	3.2	16
28	Dietary restriction affects antioxidant levels in rat liver mitochondria during ageing. Molecular Aspects of Medicine, 1997, 18, 247-250.	6.4	14
29	PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis. International Journal of Molecular Sciences, 2022, 23, 3904.	4.1	13
30	Autoantibodies against the plateletâ€derived growth factor receptor in scleroderma: Comment on the articles by Classen et al and Loizos et al. Arthritis and Rheumatism, 2009, 60, 3521-3522.	6.7	12
31	Characterization of binding and quantification of human autoantibodies to PDGFR $\hat{l}\pm$ using a biosensor-based approach. Analytical Biochemistry, 2017, 528, 26-33.	2.4	12
32	Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clinical and Experimental Rheumatology, 2015, 33, S160-7.	0.8	12
33	Coenzyme Q homologs and vitamin E in synaptic and non-synaptic occipital cerebral cortex mitochondria in the ageing rat. Molecular Aspects of Medicine, 1997, 18, 279-282.	6.4	10
34	Monounsaturated diet lowers LDL oxidisability in type IIb and type IV dyslipidemia without affecting coenzyme Q10and vitamin E contents. BioFactors, 1999, 9, 325-330.	5.4	9
35	Putative functional pathogenic autoantibodies in systemic sclerosis. European Journal of Rheumatology, 2020, 7, 181-186.	0.6	8
36	Reply. Arthritis and Rheumatology, 2017, 69, 1703-1704.	5.6	0